NASDAQ:ABIO - Arca Biopharma Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $0.58 +0.01 (+1.75 %) (As of 07/18/2018 04:00 PM ET)Previous Close$0.57Today's Range$0.56 - $0.5952-Week Range$0.45 - $2.50Volume221,302 shsAverage Volume822,170 shsMarket Capitalization$8.21 millionP/E RatioN/ADividend YieldN/ABeta1.82 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado. Receive ABIO News and Ratings via Email Sign-up to receive the latest news and ratings for ABIO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical SymbolNASDAQ:ABIO CUSIPN/A Webwww.arcabiopharma.com Phone720-940-2200 Debt Debt-to-Equity RatioN/A Current Ratio7.44 Quick Ratio7.44 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.87 per share Price / Book0.67 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-18,490,000.00 Net MarginsN/A Return on Equity-133.98% Return on Assets-113.80% Miscellaneous Employees20 Outstanding Shares13,920,000Market Cap$8.21 Arca Biopharma (NASDAQ:ABIO) Frequently Asked Questions What is Arca Biopharma's stock symbol? Arca Biopharma trades on the NASDAQ under the ticker symbol "ABIO." How were Arca Biopharma's earnings last quarter? Arca Biopharma Inc (NASDAQ:ABIO) released its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). View Arca Biopharma's Earnings History. What price target have analysts set for ABIO? 1 brokerages have issued twelve-month price targets for Arca Biopharma's stock. Their forecasts range from $2.00 to $2.00. On average, they expect Arca Biopharma's share price to reach $2.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price. View Analyst Ratings for Arca Biopharma. What is the consensus analysts' recommendation for Arca Biopharma? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arca Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Who are some of Arca Biopharma's key competitors? Some companies that are related to Arca Biopharma include Akers Biosciences (AKER), Achieve Life Sciences (ACHV), GeneNews (GNWSF), Fluoropharma Medical (FPMI), BG Medicine (BGMD), Response Genetics (RGDXQ) and Palatin Technologies (PTN). Who are Arca Biopharma's key executives? Arca Biopharma's management team includes the folowing people: Dr. Michael R. Bristow, Co-Founder, Pres, CEO & Director (Age 73)Mr. Thomas A. Keuer, Chief Operating Officer (Age 59)Mr. Christopher D. Ozeroff, Sr. VP, Gen. Counsel & Sec. (Age 59)Mr. Brian L. Selby, Chief Accounting Officer & VP of Fin. (Age 56)Monique Plamondon, VP of Regulatory Affairs & QA Has Arca Biopharma been receiving favorable news coverage? News stories about ABIO stock have trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arca Biopharma earned a media sentiment score of 0.03 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of Arca Biopharma? Shares of ABIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arca Biopharma's stock price today? One share of ABIO stock can currently be purchased for approximately $0.58. How big of a company is Arca Biopharma? Arca Biopharma has a market capitalization of $8.21 million. Arca Biopharma employs 20 workers across the globe. How can I contact Arca Biopharma? Arca Biopharma's mailing address is 11080 CIRCLEPOINT ROAD SUITE 140, WESTMINSTER CO, 80020. The biopharmaceutical company can be reached via phone at 720-940-2200 or via email at [email protected] MarketBeat Community Rating for Arca Biopharma (NASDAQ ABIO)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 61 (Vote Outperform)Underperform Votes: 84 (Vote Underperform)Total Votes: 145MarketBeat's community ratings are surveys of what our community members think about Arca Biopharma and other stocks. Vote "Outperform" if you believe ABIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABIO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What does earnings per share mean?